Kathleen B. Schwarz, Philip Rosenthal, Karen F. Murray, Jonathan R. Honegger, Winita Hardikar, Rosie Hague, Naveen Mittal, Benedetta Massetto, Diana M. Brainard, Chia‐Hsiang Hsueh, Jiang Shao, Bandita Parhy, Michael R. Narkewicz, Girish S. Rao, Suzanne Whitworth, Sanjay Bansal, William F. Balistreri – 20 June 2019 – For children under 12 years of age who have chronic hepatitis C virus (HCV) infection, there are currently no approved treatments with direct‐acting antiviral agents.

Varman T. Samuel, Max C. Petersen, Brandon M. Gassaway, Daniel F. Vatner, Jesse Rinehart, Gerald I. Shulman – 20 June 2019

Runping Liu, Jason D. Kang, R. Balfour Sartor, Masoumeh Sikaroodi, Andrew Fagan, Edith A. Gavis, Huiping Zhou, Phillip B. Hylemon, Jeremy W. Herzog, Xiaojiaoyang Li, Robert H. Lippman, Javier Gonzalez‐Maeso, James B. Wade, Siddhartha Ghosh, Emily Gurley, Patrick M. Gillevet, Jasmohan S. Bajaj – 20 June 2019 – Cirrhosis and hepatic encephalopathy (HE) is associated with an altered gut–liver–brain axis. Fecal microbial transplant (FMT) after antibiotics improves outcomes in HE, but the impact on brain function is unclear.

20 June 2019

Sílvia Vilarinho, Pramod K. Mistry – 20 June 2019 – The clinical relevance of the Human Genome Project and next‐generation sequencing technology was demonstrated for the first time in 2009, when whole‐exome sequencing (WES) provided the definitive diagnosis of congenital chloride diarrhea in an infant with presumed renal salt‐wasting disease. Over the past decade, numerous studies have shown the utility of WES for clinical diagnosis as well as for discovery of novel genetic disorders through analysis of a single or a handful of informative pedigrees.

Jiangfa Li, Jiming Wang, Shuiping Yu, Guandou Yuan, Songqing He – 20 June 2019

20 June 2019

Elizabeth J. Carey, Jennifer C. Lai, Christopher Sonnenday, Elliot B. Tapper, Puneeta Tandon, Andres Duarte‐Rojo, Michael A. Dunn, Cynthia Tsien, Eric R. Kallwitz, Vicky Ng, Srinivasan Dasarathy, Matthew Kappus, Mustafa R. Bashir, Aldo J. Montano‐Loza – 20 June 2019 – Loss of muscle mass and function, or sarcopenia, is a common feature of cirrhosis and contributes significantly to morbidity and mortality in this population.

Fasiha Kanwal, Jennifer R. Kramer, Steven M. Asch, Yumei Cao, Liang Li, Hashem B. El‐Serag – 20 June 2019 – Sustained virologic response (SVR) after direct acting antiviral agents (DAAs) holds promise for reducing hepatocellular cancer (HCC). DAAs have recently been available long enough to estimate the long‐term risk. We conducted a retrospective cohort study of hepatitis C virus (HCV) patients who achieved SVR with DAAs from 129 Veterans Health Administration hospitals between January 1, 2015, and December 31, 2015, with follow‐up through September 30, 2018.

Philip Rosenthal, Kathleen B. Schwarz, Regino P. Gonzalez‐Peralta, Chuan‐Hao Lin, Deidre A. Kelly, Scott Nightingale, William F. Balistreri, Sanjay Bansal, Maureen M. Jonas, Benedetta Massetto, Diana M. Brainard, Chia‐Hsiang Hsueh, Jiang Shao, Bandita Parhy, Suzanne Davison, Cornelia Feiterna‐Sperling, Lynette A. Gillis, Giuseppe Indolfi, Etienne M. Sokal, Karen F. Murray, Stefan Wirth – 20 June 2019 – Currently, the only approved hepatitis C virus (HCV) treatment for children aged <12 years is pegylated interferon plus ribavirin.